Antimicrobial mechanism of lantibiotics
Antimicrobial mechanism of lantibiotics
复制标题
DOI：
10.1042/bst20120190
复制
发表时间：
2012-12-01
影响因子：
3.9
通讯作者：
Sonomoto, Kenji
中科院分区：
文献类型：
--
作者：
Islam, Mohammad R.;Nagao, Jun-ichi;Sonomoto, Kenji
Lantibiotics是由核糖体合成的抗菌肽，在抗菌机制中通常靶向细胞壁前体脂质II，并通过抑制细胞壁生物合成和在靶膜上稳定孔隙形成来发挥其抑制活性。a型(I)（即nisin）和双组分（即乳酸菌素3147）抗生素最初与脂质II相互作用以稳定复合物，然后继续抑制细胞壁生物合成和孔形成。a （II）型（即nukacin ISK-1）和b型（即mersacidin）抗生素也使用脂质II作为对接分子，但只能抑制细胞壁的生物合成，不能形成孔。本文就不同类型抗生素的抑菌机理、研究进展及前景进行综述。
Lantibiotics are ribosomally synthesized antimicrobial peptides that commonly target the cell wall precursor lipid II during their antimicrobial mechanism and exert their inhibitory activity by (i) inhibition of cell wall biosynthesis, and (ii) stable pore formation in the target membrane. Type-A(I) (i.e. nisin) and two-component (i.e. lacticin 3147) lantibiotics initially interact with lipid II to stabilize the complex, which then proceeds to inhibit cell wall biosynthesis and pore formation. Type-A(II) (i.e. nukacin ISK-1) and type-B (i.e. mersacidin) lantibiotics also use lipid II as a docking molecule, but can only inhibit cell wall biosynthesis without forming pores. In the present paper, we review the antimicrobial mechanism of different types of lantibiotics, their current progress and future prospect.